Right from day one, our company has favored a partnership-based approach to research, thanks to our conviction that complementary skills and the sharing of expertise are key to successful innovation.
Our long-standing partnership with the CNRS is symbolic of the partnership-based approach that the Group has favored ever since it was created. Over the years, this approach has resulted in partnerships with several French public research establishments as well as with innovative biotechnology companies (biotechs).
In November 2015, Pierre Fabre announced a global partnership for developing and marketing two oncology molecules owned by Array.
These molecules, binimetinib and encorafenib, have reached an advanced stage of development. Binimetinib, an MEK inhibitor, and encorafenib, a BRAF inhibitor, are currently undergoing three international phase-3 clinical trials for melanoma and ovarian cancer.